Social Sentiment for PETX
Bullish vs. Bearish opinions
Weighted Sentiment 0.00
Aratana Therapeutics Forecast and Stock Analysis
Technical PETX stock analysis for Friday June 14, 2019.
Aratana Therapeutics fell by -1.85% in the last day ( Friday, 14th Jun 2019 ) from $4.87 to $4.78 and has now fallen 3 days in a row. During day the stock fluctuated 2.20% from a day low at $4.77 to a day high of $4.88. The price has fallen in 5 of the last 10 days , but is still up by 3.24% over the past 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -117 173 shares and in total 231 479 shares bought and sold for approximately $1.11 million.
Quick summary:
- 30 day high of the PETX stock price was $4.95 and low was $4.59.
- 90 day high was $5.04 and low was $3.35.
- 52 week high for the Aratana Therapeutics - $7.16 and low - $3.30.
Trend
Aratana Therapeutics lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 38.84% during the next 3 months and, with 90% probability hold a price between $6.00 and $7.83 at the end of this period.
Signals
There are few to none technical positive signals at the moment. Aratana Therapeutics holds sales signals from both short- and long-term moving averages. On corrections up there will be some resistance from the lines at $4.84 and $4.78. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Wednesday June 12, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Access today's Top 5 Golden Star Companies
Relative Strength Index (RSI)
RSI14 is 51 and the stock is currently not being overbought or oversold
Support & Resistance
Aratana Therapeutics finds support from accumulated volume at $4.76.
Risk
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
2.16 %
Average volatilityOverall risk:
Very Low Low Medium High Very High
Evaluation:
The Aratana Therapeutics stock holds several negative signals and despite the positive trend we believe Aratana Therapeutics will perform weak in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Buy Candidate to a Sell Candidate.
| Golden Star Signal |
|
Get competitive edge = |
|
The signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives a very good return. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day! Get access to Golden Star list now |
From Our Blog
- Trading With Moving Average
- Pivot Points
- Accumulated Volume - Support and Resistance
- Volume - The Indicator You Really Need to Know
- We Give Back!
- Better Buy: Amazon vs. Facebook
- Better Buy: Apple vs. Microsoft
- Relative Strength Index (RSI)
- How to Lose Money When Trading: Part 2
- How to Lose Money When Trading: A Trader is Born
- Our 2017 Christmas Donation
- The Golden Star
- Announcing Partnership With CityFALCON
- Why correct moving average matters
- NASDAQ down -4.17%. Our portfolio is up +8.56%
- New Feature Added: Golden Star Signal
- Pick a Winner With StockInvest.us
Proudly made at
in partnership with
